Fiberside Chat: In Fiber Buildouts, the Devil is in the Details

 

With the development of technology like 5G and fiber networks, society is moving at breakneck speed toward faster and more efficient ways of life. But what is it costing us?

Tom Counts, Executive Vice President and Co-founder of 3-GIS, has noticed in recent months a strange and puzzling trend in the world of fiber – one that has given him cause for concern. As he revealed to host Tyler Kern in this episode, more companies are trying to cash in on the hidden opportunities found in fiber network buildouts. But, in the rush to do so, they’re cutting corners and making mistakes.

“I think it’s a perfect example of, ‘You don’t know what you don’t know,’” Counts said. “People are getting into the engineering side that, while they’re well-intended and may understand the electric market, the municipal market, the co-operative market, I can’t confidently say that they understand the fiber telecommunications market.”

So, what can fiber companies, or what Counts calls the “fiber consortium,” do about this?

“We’ve got to do a better job educating our users on what we need to be providing to our field crew, what we need to be providing to our cities for permitting, what we need to be providing to every single person involved in the design and construction to make sure it’s good and efficient,” Counts mused.

Subscribe to the Fiberside Chat podcast on Apple Podcasts and Spotify for the latest interviews and other thought leadership content from the world of fiber networks.

Follow us on social media for the latest updates in B2B!

Twitter – @MarketScale
Facebook – facebook.com/marketscale
LinkedIn – linkedin.com/company/marketscale

Follow us on social media for the latest updates in B2B!

Image

Latest

vitro
Analyzing the Suppressive TME in In Vitro Based Assays
April 19, 2025

In the rapidly advancing field of cancer immunotherapy, accurately modeling the tumor microenvironment (TME) has become essential to improving the predictive power of preclinical drug testing. As immune-modulating therapies surge forward, with over 4,000 immune modulators in development globally, scientists are refining assay technologies that maintain the complexity of patient-specific tumor biology. In vitro platforms…

Read More
cancer
Targeting T Cells Within the Cancer Immunity Cycle
April 19, 2025

As cancer immunotherapy continues to reshape treatment landscapes, fine-tuning T-cell responses has become a critical frontier. Recent advances in 3D organoid models and high-content imaging are enabling scientists to closely mimic patient-specific tumor environments—unlocking insights into how T cells behave, respond, and falter under immune checkpoint blockade. With over 4,000 immune modulators in clinical…

Read More
cancer Immunity cycle
Advanced In Vitro Technologies to Investigate Therapeutic Impact on the Cancer Immunity Cycle
April 19, 2025

As immunotherapy revolutionizes cancer treatment, the need for physiologically relevant preclinical models becomes more urgent than ever. Despite the success of immune checkpoint inhibitors, a large majority of patients fail to achieve long-lasting responses, prompting researchers to explore more complex and predictive assays. The cancer immunity cycle, first described in 2013, remains a central framework…

Read More
resistance
Inside Oncology Drug Development: Overcoming Resistance with Science
April 19, 2025

In the last two decades, oncology has undergone a transformation with over 300 new cancer therapies approved by the FDA—many offering novel mechanisms of action. Despite these innovations, resistance to treatment remains a critical challenge, with cancer cells evolving or adapting to evade even the most advanced therapeutics. This issue is particularly pressing given that…

Read More